相关实验视频

Updated: Jan 8, 2026

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Published on: November 28, 2015

CD58通过PD-L1上调来重塑质瘤中的免疫抑制微环境

Siqi Gou¹, Pengfei Zhao², Lei Zong³

¹Department of Pathology, Xi'an No. 3 Hospital, The Affiliated Hospital of Northwest University, Xi'an, Shaanxi, China.

Frontiers in oncology

|December 24, 2025

概括

集群差异化58 (CD58) 通过增加PD-L1和创建免疫抑制瘤微环境,促进质瘤的进展. 向CD58-PD-L1通路可能会改善质瘤免疫疗法.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
分子生物学分子生物学

背景情况:

差异化58集群 (CD58) 是一个免疫调节器,参与瘤免疫逃避.
它在质瘤的免疫抑制微环境和编程死亡链接1 (PD-L1) 调节中的确切作用尚未完全理解.

研究的目的:

研究CD58在质瘤中的临床和机械学意义.
确定CD58是否影响瘤微环境和质瘤中的PD-L1表达.

主要方法:

对TCGA和CGGA数据集的综合生物信息学分析.
在体外研究涉及CD58在质瘤细胞系中被淘汰 (U87MG,LN229).
评估了CD58表达,免疫细胞透,PD-L1水平和细胞因子分泌 (CCL5,CXCL9,CXCL10).

主要成果:

CD58表达在高度质瘤中升高,与临床指标相关.
CD58 knockdown 抑制了结质瘤细胞的增殖,迁移和入侵.
沉默CD58降低了PD-L1和维丁,上调了ICAM-1和增加了化学激素分泌.

结论:

CD58通过PD-L1上调和免疫抑制微环境促进质瘤的进展.
CD58是一种潜在的预后生物标志物和质瘤的治疗点.
向CD58-PD-L1轴可以提高质瘤免疫疗法的疗效.

关键词:

CD58 CD58 CD58 CD58 CD58 CD58 CD58 CD58 CD58 CD58 CD58 CD58 CD58 在 ICAM-1 中,在PD-L1中.这是一种化学物质,chemokine.质瘤是一种质瘤.微观环境是一个微观环境.

更多相关视频

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.